Vivus: into single digits Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus: into single digits

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: MIKE DUBIS who wrote (256)	4/19/1998 2:44:00 PM
From: Mkilloran	Read Replies (1) of 1016

Mike........we'll all know the answer to your question this summer. Look for the script data from the UK and sales reported in 2nd qtr. USA script data in June should be the start of any reasonable comparison as to how well/poor Vivus's Muse will do in a market shared with Pfe's Viagara. Third qtr will show results with Argentina, Brazil, S Korea and Switzerland and any additional countries that gain approval in the near term. New and improved Muse II in phase 3 trials...will hit the market in 1999.....The company will survive and have good sales IMO. If it only has a marginal market acceptance it will be a buyout candidate by someone bigger...Management will be purged,etc. IMO the stock will go higher from here in either case. My money is on a successful product with a nice percent of the ED market with new non-ED products to push them higher in the future.... Time will tell....You bet RED I'am betting Black....(the bottom line).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next